Search Results
Your search for 3 matches 15340 pages
Showing 14401 - 14450Addition of Ofatumumab to Chlorambucil Increases Progression-Free Survival in Previously Untreated CLL Patients Who Are Not Candidates for Fludarabine
In the phase III COMPLEMENT 1 trial reported in The Lancet, Hillmen et al found that the addition of the anti-CD20 antibody ofatumumab (Arzerra) to chlorambucil (Leukeran) increased progression-free survival among patients with chronic lymphocytic leukemia (CLL) who were not considered candidates...
No Improvement in Undetectable PSA Rate With Cixutumumab Plus Androgen-Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer
In a randomized phase II trial (SWOG S0925) reported in the Journal of Clinical Oncology, Yu et al found that the addition of cixutumumab to androgen-deprivation therapy did not significantly increase the rate of undetectable prostate-specific antigen (PSA) in patients with newly diagnosed...
Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer
In the phase III RAISE trial reported in The Lancet Oncology, Tabernero et al found that the addition of the antiangiogenic anti-VEGFR2 antibody ramucirumab (Cyramza) to second-line FOLFIRI (leucovorin, fluorouracil, irinotecan) improved overall survival in patients with metastatic colorectal...
Eligible for Breast-Conserving Therapy, Many Still Choose Mastectomy
No approved targeted therapies exist to treat triple-negative breast cancer, but new chemotherapeutic treatment strategies are helping shrink tumors so that less breast tissue needs to be removed during surgery. New research led by Brigham and Women's Hospital finds that breast-conserving therapy...
Afatinib Improves Progression-Free Survival vs Methotrexate in Platinum-Treated Recurrent or Metastatic Head and Neck Cancer
In the phase III LUX-Head & Neck 1 trial reported in The Lancet Oncology, Machiels et al found that afatinib (Gilotrif) improved progression-free survival vs methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum...
AACR 2015: Olaparib and Investigational PI3K Inhibitor BKM120 Combination Active Against Ovarian and Breast Cancer Subtypes
Combination treatment with the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the investigational phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade...
AACR 2015: Combining Two Investigational Immunotherapy Drugs Safe, With Early Signs of Effectiveness
Combining the immunostimulatory anti-CD40 monoclonal antibody CP-870,893 with the immune checkpoint inhibitor tremelimumab was found to be safe, with clinical evidence of response in patients with advanced melanoma, according to phase I clinical trial data presented at the AACR Annual Meeting 2015, ...
AACR 2015: Investigational PD-L1–Targeted Immunotherapy Safe for Patients With Triple-Negative Breast Cancer, Effective in Some
The investigational immunotherapy MPDL3280A was safe, tolerable, and showed early signs of durable clinical activity in patients with metastatic triple-negative breast cancer, according to data from a first-in-human phase I clinical trial presented at the AACR Annual Meeting 2015, held April 18 to...
Excessive All-Cause and Second Primary Malignancy-Related Mortality and Frequent Late Morbidity in Hodgkin Lymphoma Patients Treated During Adulthood
In a single-institution study reported in the Journal of the National Cancer Institute, Matasar et al found that Hodgkin lymphoma patients treated during adulthood were at increased risk of all-cause and second primary malignancy mortality compared with SEER (Surveillance, Epidemiology, and...
AACR 2015: Pembrolizumab Shows Promise in Non–Small Cell Lung Cancer
The immunotherapy pembrolizumab (Keytruda) was found to be safe and yielded durable responses in patients with advanced, non–small cell lung cancer (NSCLC). Those with high levels of the protein PD-L1 in their tumors had better clinical outcomes, according to phase I KEYNOTE-001 clinical...
AACR 2015: Pembrolizumab Is Better Than Ipilimumab for Advanced Melanoma in Phase III Trial
In the first randomized trial to compare two U.S. Food and Drug Administration–approved immune checkpoint inhibitors as first-line therapy for patients with advanced melanoma, pembrolizumab (Keytruda) yielded significantly better treatment outcomes than ipilimumab (Yervoy) for all endpoints...
AACR 2015: New T Cell–Based Immunotherapy Shows Promise for Lethal Stem Cell Transplant Complication
More than 60% of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was nonresponsive to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus–specific cytotoxic T-lymphocyte (EBV-CTL) therapy....
Glembatumumab Vedotin Appears Active in Heavily Treated Advanced Glycoprotein NMB–Overexpressing Breast Cancer and Triple-Negative Disease
In the randomized phase II EMERGE study reported in the Journal of Clinical Oncology, Yardley et al found that the anti–glycoprotein NMB (gpNMB) antibody-drug conjugate glembatumumab vedotin may improve response rate over alternative chemotherapy in patients with advanced refractory breast...
Physical Activity Helps Cancer Survivors Fend Off Side Effects
Three or more hours of walking per week can boost the vitality and health of prostate cancer survivors. Men and women who have survived colorectal cancer and are regular walkers also reported lower sensations of burning, numbness, tingling, or loss of reflexes that many often experience after...
Ibrutinib Is Highly Active in Previously Treated Waldenström’s Macroglobulinemia
In a study reported in The New England Journal of Medicine, Treon et al found that ibrutinib (Imbruvica) was highly active and produced durable responses in patients with previously treated Waldenström’s macroglobulinemia. Response rates were highest in patients with MYD88 mutation and...
Similar Outcomes With Laparoscopic vs Open Resection in Rectal Cancer
In the COLOR II study reported in The New England Journal of Medicine, Bonjer et al found similar rates of locoregional recurrence and disease-free and overall survival with laparoscopic vs open resection of rectal cancer. Study Details In the trial, 1,044 patients from 30 sites in 8 countries in ...
No Survival Benefit of Vorinostat in Progressive Advanced Malignant Pleural Mesothelioma
In the phase III VANTAGE-014 study reported in The Lancet Oncology, Krug et al found that treatment with the histone deacetylase inhibitor vorinostat (Zolinza) did not improve overall survival vs placebo in patients with malignant pleural mesothelioma who had progressed on previous chemotherapy....
Patients With Relapsed or Refractory CLL Who Discontinue Ibrutinib Early Have Poor Outcomes
Most patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who discontinued ibrutinib (Imbruvica) early “were difficult to treat and had poor outcomes,” according to a study of patients enrolled in four different clinical trials of ibrutinib, with or without rituximab...
Study Finds Link Between Muscle-Building Supplements and Testicular Cancer
Men who reported taking muscle-building supplements, such as pills and powders with creatine or androstenedione, reported a significantly higher likelihood of having developed testicular cancer than men who did not use such supplements, according to a study by Li et al in the British Journal of...
Platinum Monotherapy Particularly Active in BRCA1/2-Mutant Metastatic Triple-Negative Breast Cancer
In the phase II TBCRC009 trial reported in the Journal of Clinical Oncology, Isakoff et al found that platinum monotherapy was active in treatment of metastatic triple-negative breast cancer, particularly in cases with BRCA1/2 mutation, and that an assay of genomic instability characteristic of...
Increasing Number of Boys Vaccinated Against HPV Could Protect More People at the Same Price
Public health programs that devote a portion of their funding to encourage more boys to be vaccinated against human papillomavirus (HPV)—rather than merely attempting to raise coverage among girls—may ultimately protect more people for the same price, a study from Duke University...
Complete Regression of Metastatic Cervical Cancer Is Observed After Treatment With HPV-Targeted Tumor-Infiltrating T Cells
As reported in the Journal of Clinical Oncology, Stevanovíc et al observed complete regression of metastatic cervical tumors in two patients following a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells. In the protocol, nine patients with metastatic cervical ...
Durable Responses With Nivolumab in Previously Treated Advanced Renal Cell Carcinoma
In a phase I cohort-expansion study reported in the Journal of Clinical Oncology, McDermott et al found that nivolumab (Opdivo) produced durable responses in patients with previously treated advanced renal cell carcinoma. Responses continued after nivolumab discontinuation in some patients. Study...
Stereotactic Body Radiotherapy Plus Cetuximab Appears Safe, Effective in Previously Irradiated Recurrent Head and Neck Squamous Cell Carcinoma
In patients with previously irradiated recurrent squamous cell carcinoma of the head and neck, the combination of stereotactic body radiation therapy plus cetuximab (Erbitux) appears to be safe and effective, according to a study by Vargo et al in the International Journal of Radiation Oncology...
Worse Outcomes With Lapatinib vs Trastuzumab Plus Taxane in Advanced HER2-Positive Breast Cancer
In the phase III National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.31 trial, first-line treatment with lapatinib (Tykerb) vs trastuzumab (Herceptin) combined with a taxane was associated with poorer progression-free survival and greater toxicity in patients with advanced...
One in Five Medicare Patients With Melanoma Experience Surgical Delays
A large retrospective cohort study of more than 32,000 Medicare beneficiaries diagnosed with melanoma has found that one in five patients experience a delay of surgery that is longer than 1.5 months. Those patients undergoing biopsy and surgery by dermatologists had the lowest risk for delay, which ...
Adjuvant Ipilimumab Increases Recurrence-Free Survival vs Placebo After Complete Resection of High-Risk Stage III Melanoma
In the phase III EORTC 18071 trial reported in The Lancet Oncology, Eggermont et al found that adjuvant ipilimumab (Yervoy) significantly improved recurrence-free survival vs placebo in patients with completely resected stage III melanoma at high risk of disease recurrence. Ipilimumab was...
FDA Grants Breakthrough Therapy Designation to Rucaparib in Advanced Ovarian Cancer With BRCA Mutations
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Clovis Oncology’s investigational agent rucaparib as monotherapy treatment of advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with...
Persistence of HER2-Specific CAR T Cells in HER2‑Positive Sarcoma
In a phase I/II study reported in Journal of Clinical Oncology, Ahmed et al found that infusion of T cells expressing HER2-specific chimeric antigen receptor (CAR) with a CD28.ζ signaling domain (HER2-CAR T cells) could produce persistent CAR T cell levels for ≥ 6 weeks in patients with...
Five-Year Analysis Indicates Potential for Long‑Term Survival With Ipilimumab Plus Dacarbazine in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Maio et al found a 5-year survival rate of 18% among treatment-naive patients receiving ipilimumab (Yervoy) plus dacarbazine in a phase III trial. The findings support other data indicating long-term survival in some patients receiving...
Erythropoietin Plus Radiation Therapy Does Not Improve Local-Regional Control in Anemic Patients With Head and Neck Cancer
Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiation therapy or chemoradiation, according to a study published...
Improved Progression-Free Survival With Brentuximab Vedotin Consolidation After Transplantation in Hodgkin Lymphoma
In the phase III AETHERA trial reported in The Lancet, Moskowitz et al found that brentuximab vedotin (Adcetris) consolidation therapy after autologous stem cell transplantation prolonged progression-free survival by 18 months vs placebo in patients with Hodgkin lymphoma at risk for relapse or...
Nocturnal Cortisol Levels May Provide a Noninvasive Biomarker of Ovarian Cancer Severity
Elevated nocturnal cortisol levels prior to surgery in patients with ovarian cancer were associated with shorter survival time, according to a study by Schrepf et al in Psychoneuroendocrinology. Thus, night-time cortisol levels may prove to be a noninvasive biomarker of ovarian cancer disease...
Substantial Pathologist Diagnostic Disagreement for Breast Biopsy Specimens
In a study reported in JAMA, Elmore et al found a substantial rate of disagreement between pathologist diagnosis based on single breast biopsy slides and the consensus-derived diagnosis of a panel of pathologists. Disagreement rates were highest for ductal carcinoma in situ (DCIS) and atypical...
Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma With Progression After Anti–CTLA-4 Treatment
In the phase III CheckMate 037 trial reported in The Lancet Oncology, Weber et al found that treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in a significantly greater response rate vs chemotherapy as second- or later-line treatment in patients with advanced melanoma progressing after ...
Liver-Sparing Surgery Associated With Higher Survival Rates in Cancer Patients
According to researchers at Memorial Sloan Kettering Cancer Center (MSKCC), hepatic parenchymal preservation, in which a surgeon removes less than a lobe of the liver in a patient undergoing an operation for liver cancer, is associated with lower mortality and complication rates. Their study...
No Differences in Patient-Reported Outcomes or Resource Use With Early vs Delayed Initiation of Palliative Care Intervention
In the ENABLE III study reported in the Journal of Clinical Oncology, Bakitas et al found that early vs delayed initiation of a palliative care intervention did not result in improved patient-reported outcomes or resource use. Early initiation was associated with better 1-year survival. Study...
Reduced Family Caregiver Depression With Early vs Delayed Palliative Care Intervention for Caregivers
In the ENABLE III study reported in the Journal of Clinical Oncology, Dionne-Odom et al found that early vs delayed use of a palliative care intervention for family caregivers of patients with advanced cancer reduced caregiver depression scores and caregiver stress burden. No differences in...
Study Finds Both the Number of Childhood Cancer Survivors and the Prevalence of Morbidity Are Increasing
Researchers investigating the prevalence of childhood cancer survivors and the population-level burden of morbidity in these survivors have found that although the number of childhood cancer survivors has increased by nearly 60,000 since 2005, the majority of those who have survived 5 or more years ...
Sentinel Lymph Node Mapping Identifies Positive Lymph Nodes in Women With High-Risk Endometrial Cancer
In a study of women with high-grade endometrial cancer, researchers at The University of Texas MD Anderson Cancer Center found sentinel lymph node mapping accurately identified all women with node-positive, high-risk endometrial cancer, when prospectively compared to a complete pelvic and...
Italian Trial Shows Benefit of Dose-Dense Adjuvant Therapy With Sequential Epirubicin-Cyclophosphamide-Paclitaxel in Early Node-Positive Breast Cancer
In an Italian 2×2 phase III trial reported in The Lancet, Del Mastro et al found that dose-dense adjuvant therapy with sequential epirubicin, cyclophosphamide, and paclitaxel (EC-P) with or without fluorouracil (5-FU) increased disease-free survival vs standard-interval therapy in early-stage ...
Panobinostat and Carfilzomib Combination Appears Safe and Effective in Relapsed/Refractory Multiple Myeloma
In patients with relapsed/refractory multiple myeloma, the combination of panobinostat (Farydak) and carfilzomib (Kyprolis) appears to be safe and effective, according to a phase I/II study by Berdeja et al in Haematologica. Further evaluation of this combination treatment is warranted to establish ...
No Survival Benefit of IGF-1R/Insulin Receptor Inhibitor Linsitinib in Advanced Adrenocortical Carcinoma
In a phase III trial reported in The Lancet Oncology, Fassnacht et al found that linsitinib, an insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor inhibitor, did not improve overall survival vs placebo in patients with previously treated locally advanced or metastatic...
American Gastroenterological Association Releases New Guidelines on the Management of Asymptomatic Neoplastic Pancreatic Cysts
The growing use of sophisticated abdominal imaging techniques, which has led to a marked increase in the findings of incidental pancreatic cysts, has prompted the American Gastroenterological Association (AGA) to issue new recommendations in the management of asymptomatic neoplastic pancreatic...
No Improvement in Complete Remission Rate With Cytarabine Plus Amonafide L-Malate vs Daunorubicin in Secondary AML
In a phase III trial reported in the Journal of Clinical Oncology, Stone et al found that the combination of cytarabine and amonafide L-malate, a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor, did not improve complete remission rate compared with cytarabine plus...
PET-Adapted Sequential Salvage Therapy With Brentuximab and Augmented ICE Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
In a phase II study reported in The Lancet Oncology, Moskowitz et al found that a salvage strategy involving brentuximab vedotin (Adcetris) treatment followed by 18F-fluorodeoxyglucose positron-emission tomography (PET) and augmented ifosfamide, carboplatin, and etoposide (ICE) in PET-positive...
No Difference in Event-Free Survival With Stem Cell Transplantation Using Matched Unrelated vs Sibling Donor Grafts in Children With ALL
In a European trial (Berlin-Frankfurt-Muenster study group trial ALL-SCT-BFM 2003) reported in the Journal of Clinical Oncology, Peters et al found no difference in event-free survival with stem cell transplantation using matched unrelated vs sibling donors in pediatric patients with high-risk...
European Retrospective Study Shows Activity of Crizotinib in Advanced Lung Adenocarcinoma With ROS1 Rearrangement
In a retrospective study in the European EUROS1 cohort reported in the Journal of Clinical Oncology, Mazières found that crizotinib (Xalkori) treatment was associated with an 80% response rate in patients with stage IV lung adenocarcinoma with ROS1 rearrangement. Study Details The study...
Addition of Lenalidomide to Docetaxel-Prednisone Worsens Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
In the phase III MAINSAIL trial reported in The Lancet Oncology, Petrylak et al found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer was associated with significantly worse overall survival. The...
Comprehensive Genomic Profiling Shows Distribution of Targetable Alterations in Carcinomas of Unknown Primary Site
In a study reported in JAMA Oncology, Ross et al found potentially targetable genomic alterations in most carcinomas of unknown primary site using comprehensive genomic profiling. Adenocarcinomas of unknown primary site frequently harbored receptor tyrosine kinase/Ras/MAPK pathway alterations....
